Sclerostin is overexpressed by plasma cells from multiple myeloma patients

Annals of the New York Academy of Sciences

Volumn 1237, Issue 1, 2011, Pages 19-23

  Brunetti, Giacomina ^a   Oranger, Angela ^a   Mori, Giorgio ^b   Specchia, Giorgina ^c   Rinaldi, Erminia ^c   Curci, Paola ^c   Zallone, Alberta ^a   Rizzi, Rita ^c   Grano, Maria ^a   Colucci, Silvia ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

MM cells; Multiple myeloma; Osteolysis; Sclerostin

Indexed keywords

SCLEROSTIN;

ADULT; ARTICLE; BONE DISEASE; BONE MARROW; CANCER PATIENT; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOBLAST; PLASMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

EID: 81255210568     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06196.x     Document Type: Article

References (11)

1. Roodman, G.D. 2010. Pathogenesis of myeloma bone disease. J. Cell Biochem. 109: 283-291.
2. Krishnan, V., H.U. Bryant & O.A. Macdougald 2006. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116: 1202-1209.
3. Ducy, P. et al 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
4. Moester, M.J. et al 2010. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 87: 99-107.
5. Kyle, R.A. & S.V. Rajkumar 2009. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23: 3-9.
6. International Myeloma Working Group. 2003. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121: 749-757.
7. Greipp, P.R. et al 2005. International staging system for multiple myeloma. J. Clin. Oncol. 23: 3412-3420.
8. Colucci, S. et al 2004. T cells support osteoclastogenesis in anin vitromodel derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730.
9. Gaudio, A. et al 2010. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J. Clin. Endocrinol. Metab. 95: 2248-2253.
10. Appel, H. et al 2009. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60: 3257-3262.
11. Terpos, E. et al 2010. Circulating levels of the Wnt inhibitors Dickkopf-1 and sclerostin in different phases of multiple myeloma: alterations post-therapy with lenalidomide and dexamethasone with or without bortezomib. (ASH Annual Meeting Abstracts). Blood 116: (Abstract 2963).